Breaking News

Fujifilm Boosts Production of Avigan Tablet for COVID-19

Expands manufacturing capacity at Fujifilm Toyama Chemical to increase production of its influenza antiviral drug

By: Contract Pharma

Contract Pharma Staff

Fujifilm Corporation has expanded its manufacturing capacity at Fujifilm Toyama Chemical Co., Ltd. to significantly increase production of its influenza antiviral drug Avigan Tablet (favipiravir) for treating patients with COVID-19.   To further boost the supply of Avigan, Fujifilm is allocating additional capacity at its Fujifilm Wako Pure Chemical Co., Ltd. facility in Japan, for production of pharmaceutical intermediates used to manufacture Avigan. In addition, Fujifilm has established stra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters